QuidelOrtho (QDEL) Projected to Post Quarterly Earnings on Wednesday

QuidelOrtho (NASDAQ:QDEL) is anticipated to issue its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect QuidelOrtho to post earnings of $0.54 per share and revenue of $699.7950 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

QuidelOrtho Trading Up 1.4%

Shares of QDEL stock opened at $29.10 on Monday. The company’s 50-day moving average price is $29.59 and its 200-day moving average price is $27.71. The company has a current ratio of 1.78, a quick ratio of 0.98 and a debt-to-equity ratio of 1.23. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -1.71 and a beta of 0.68. QuidelOrtho has a twelve month low of $19.50 and a twelve month high of $43.92.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. UBS Group upped their target price on QuidelOrtho from $31.00 to $35.00 and gave the company a “neutral” rating in a research note on Wednesday, January 21st. JPMorgan Chase & Co. reduced their target price on shares of QuidelOrtho from $26.00 to $22.00 and set an “underweight” rating on the stock in a report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of QuidelOrtho in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 13th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $39.00.

Insider Buying and Selling at QuidelOrtho

In other QuidelOrtho news, CFO Joseph M. Busky purchased 4,770 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were bought at an average price of $26.06 per share, with a total value of $124,306.20. Following the completion of the transaction, the chief financial officer directly owned 6,920 shares in the company, valued at $180,335.20. This trade represents a 221.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Brian J. Blaser acquired 23,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 19th. The shares were bought at an average price of $21.34 per share, for a total transaction of $501,490.00. Following the completion of the acquisition, the chief executive officer owned 29,533 shares of the company’s stock, valued at $630,234.22. This trade represents a 389.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 29,390 shares of company stock worth $657,340. 0.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC lifted its holdings in QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after acquiring an additional 886 shares during the period. Larson Financial Group LLC raised its holdings in QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares during the period. EverSource Wealth Advisors LLC increased its holdings in QuidelOrtho by 250.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after acquiring an additional 2,309 shares during the period. Osaic Holdings Inc. raised its position in shares of QuidelOrtho by 298.1% in the second quarter. Osaic Holdings Inc. now owns 3,300 shares of the company’s stock worth $95,000 after buying an additional 2,471 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of QuidelOrtho by 230.5% during the 2nd quarter. State of Wyoming now owns 4,524 shares of the company’s stock valued at $130,000 after acquiring an additional 3,155 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.